BioCardia Inc. Common Stock (BCDA)
Stock · NASDAQ · Health Care
$0.92as of 10/16/2026
Price chart
Active signals
BCDA Signal Track Record
How signals performed across all stocks →What BCDA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -5.2% | 35% | September 14, 2026 |
| Bollinger Band BreakdownActive now | 23 | +1.0% | 52% | May 15, 2026 |
| Bollinger Band Breakout | 20 | -13.3% | 20% | August 26, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -5.7% | 36% | August 31, 2026 |
| Any 20-session window (baseline) | -4.0% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 17
- Website
- www.biocardia.com/
Fundamentals
- 1-day range
- $0.9102$0.961
- Market cap
- $10.80M
- P/E (trailing)
- —
- P/E (forward)
- -1.59
- EPS (trailing)
- $-0.80
- Dividend yield
- —
- Beta
- 0.63
- Avg. volume
- 254.8K
- Dividend pay date
- June 6, 2019
How BioCardia Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 26, 2025 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
BioCardia Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BCDABioCardia Inc. Common Stock$0.92▼ 2.13%Market cap $10.80MP/E —$0.75$1.8
- SNTISenti Biosciences Holdings Inc. Common Stock$0.225▼ 14.12%Market cap $11.18MP/E —$0.2399$2.88
- INTSIntensity Therapeutics Inc. Common stock$3.35▼ 0.89%Market cap $11.49MP/E —$3.1$43.5
- INABIN8bio Inc. Common Stock$1.11▼ 6.33%Market cap $9.55MP/E —$0.88$2.73
- CRISCuris Inc. Common Stock$0.41▼ 19.61%Market cap $8.59MP/E —$0.5733$33.6
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BCDA BioCardia Inc. Common Stock | $10.80M | — | $0.92 | ▼ 2.13% | $0.75$1.8 |
| SNTI Senti Biosciences Holdings Inc. Common Stock | $11.18M | — | $0.225 | ▼ 14.12% | $0.2399$2.88 |
| INTS Intensity Therapeutics Inc. Common stock | $11.49M | — | $3.35 | ▼ 0.89% | $3.1$43.5 |
| INAB IN8bio Inc. Common Stock | $9.55M | — | $1.11 | ▼ 6.33% | $0.88$2.73 |
| CRIS Curis Inc. Common Stock | $8.59M | — | $0.41 | ▼ 19.61% | $0.5733$33.6 |
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific MeetingYahoo · 10/7/2026
- BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heartbenzinga · 10/1/2026
- BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ CatheterYahoo · 10/1/2026
- BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The HeartBenzinga · 10/1/2026
- BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin SubmissionYahoo · 9/23/2026
- BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter SystemBenzinga · 9/23/2026
- BioCardia Shares Fall 10% After Hours: Here's WhyBenzinga · 9/22/2026
- Top movers in Monday's after hours sessionChartMill · 9/21/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 9/16/2026
Insider Activity
Insider Actions →- Altman Peter · September 23, 2026 · Buy1.9K @ $1.05
- Altman Peter · September 3, 2026 · Buy800 @ $1.09
- Altman Peter · August 17, 2026 · Buy5.4K @ $0.93
- Altman Peter · August 13, 2026 · Buy1.9K @ $0.92
- Altman Peter · July 29, 2026 · Buy5.0K @ $0.78
- Altman Peter · July 17, 2026 · Buy500 @ $0.83
- Altman Peter · July 15, 2026 · Buy1.5K @ $0.86
- Altman Peter · July 14, 2026 · Buy2.8K @ $0.88
- Altman Peter · July 10, 2026 · Buy1.0K @ $0.94
- Altman Peter · July 9, 2026 · Buy1.0K @ $0.9
- Altman Peter · July 8, 2026 · Buy5.5K @ $0.97
- Altman Peter · July 8, 2026 · Buy5.4K @ $0.9645
- Facteau Bill · July 6, 2026 · Grant8.0K
- Marvin Slosman · July 6, 2026 · Grant8.0K
- Blank Andrew Scott · July 6, 2026 · Grant8.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 620.0K
- Total value held
- $725.6K
- Institutional holders
- 16
- Unknown130.0K
- Unknown124.6K
- Unknown94.3K
- Unknown63.4K
- Unknown38.8K
- Unknown35.7K
- Unknown35.5K
- Unknown24.3K
- Unknown20.4K
- Unknown18.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioCardia Resubmits Helix Catheter Pre-Submission to FDA
BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.
BioCardia Resubmits Helix Catheter Pre-Submission to FDA. BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.